Acromegaly Pipeline| 15+ Key Players & 15+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

DelveInsight's, "Acromegaly Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Acromegaly pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Acromegaly Pipeline Insight report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acromegaly collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

Key takeaways from the Acromegaly Pipeline Report
• DelveInsight's Acromegaly Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading Acromegaly Companies are working such as Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health Inc, Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Promising Acromegaly Pipeline therapies such as octreotide, IONIS-GHR-LRx, SRL, Paltusotine, Octreotide Capsules, and others.
• The Acromegaly Companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve Acromegaly.

Recent Developmental Activities in the Acromegaly Pipeline Report
• Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin type 2 receptor. It was designed by the Crinetics discovery team to provide a once daily oral option for patients with acromegaly and neuroendocrine tumors that are currently treated by injected therapies that sell approximately $3.1 billion annually. Non-clinical chronic toxicology studies are complete and no dose limiting toxicity was identified at the maximum feasible doses in rats and dogs. Crinetics previously completed a Phase 1 trial that showed potent suppression of the growth hormone (GH) axis in healthy volunteers, which provided clinical proof-of-concept. In addition, the molecule's observed plasma half-life of approximately 2 days suggested the potential for paltusotine for once daily oral administration. A subsequent Phase 1 trial showed that paltusotine was 70% orally bioavailable. Paltusotine is an investigational drug currently undergoing two Phase 2 clinical trials for the treatment of acromegaly, the ACROBAT Edge and Evolve trials. Paltusotine has been discovered, characterized, and developed by Crinetics and U.S. patents have been issued covering paltusotine to 2037. Currently, it is in Phase III stage of development to treat Acromegaly.
• IONIS-GHR-LRx is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of the growth hormone receptor (GHr) to decrease the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone. When produced in excess, IGF-1 results in acromegaly, a chronic, slowly progressing and life-threatening disease. Currently, it is in Phase II stage of development to treat Acromegaly.

Request a sample and discover the recent advances in Acromegaly Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acromegaly Overview
Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. In adults, too much of this hormone causes bones, cartilage, body organs, and other tissues to increase in size. Common changes in appearance include enlarged or swollen nose, ears, hands, and feet. Acromegaly is most often diagnosed in middle-aged adults, but symptoms can appear at any age. In children, too much growth hormone causes a condition called gigantism NIH external link rather than acromegaly. Gigantism occurs when excess GH begins before the end of puberty, when children's growth plates fuse or close. Having too much GH before the growth plates close causes children to grow tall in height.

Acromegaly Emerging Drugs
• IONIS-GHR-LRX: Ionis Pharmaceuticals
• Paltusotine: Crinetics Pharmaceuticals

Acromegaly Pipeline Therapeutics Analysis
There are approx. 15+ key companies which are developing the therapies for Acromegaly. The companies which have their Acromegaly drug candidates in the most advanced stage, i.e. phase III include, Crinetics Pharmaceuticals.

Learn more about the emerging Acromegaly Treatment Landscape @ https://www.delveinsight.com/sample-request/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acromegaly Pipeline Report
• Coverage- Global
• Acromegaly Assessment by Product Type
• Acromegaly Assessment by Stage and Product Type
• Acromegaly Assessment by Route of Administration
• Acromegaly Assessment by Stage and Route of Administration
• Acromegaly Assessment by Molecule Type
• Acromegaly Assessment by Stage and Molecule Type
• Acromegaly Companies- Ionis Pharmaceuticals, Crinetics Pharmaceuticals, Camurus, Ono Pharmaceutical, Aquestive Therapeutics, Strongbridge Biopharma, Italfarmaco, Ipsen, Antisense Therapeutics, Dauntless Pharmaceuticals, TTY Biopharm, Peptron, DexTech Medical AB, Rani Therapeutics, OPKO Health Inc, Amolyt Pharma, Foresee Pharmaceuticals, ADVANZ PHARMA, and others.
• Acromegaly Pipeline therapies such as octreotide, IONIS-GHR-LRx, SRL, Paltusotine, Octreotide Capsules, and others.

Table of Content
1. Introduction
2. Executive Summary
3. Acromegaly: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Paltusotine: Crinetics Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. IONIS-GHR-LRX: Ionis Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. RaniPill: Rani Therapeutics
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. AZP-3800: Amolyt Pharma
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Acromegaly Key Companies
20. Acromegaly Key Products
21. Acromegaly- Unmet Needs
22. Acromegaly- Market Drivers and Barriers
23. Acromegaly- Future Perspectives and Conclusion
24. Acromegaly Analyst Views
25. Acromegaly Key Companies
26. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Acromegaly drugs?
• How many Acromegaly drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acromegaly?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acromegaly therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acromegaly and their status?
• What are the key designations that have been granted to the emerging drugs?

For more information about the Acromegaly Pipeline Drugs @ https://www.delveinsight.com/report-store/acromegaly-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.